KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non Operating Income (2016 - 2017)

Historic Non Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 3 years, with Q1 2017 value amounting to -$1.5 million.

  • Jazz Pharmaceuticals' Non Operating Income fell 7875.46% to -$1.5 million in Q1 2017 from the same period last year, while for Mar 2017 it was -$3.0 million, marking a year-over-year decrease of 8727.61%. This contributed to the annual value of $1.4 million for FY2015, which is 8335.83% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Non Operating Income of -$1.5 million as of Q1 2017, which was down 7875.46% from -$749000.0 recorded in Q3 2016.
  • Jazz Pharmaceuticals' Non Operating Income's 5-year high stood at $2.2 million during Q1 2015, with a 5-year trough of -$1.9 million in Q2 2015.
  • In the last 3 years, Jazz Pharmaceuticals' Non Operating Income had a median value of -$819000.0 in 2016 and averaged -$226714.3.
  • Over the last 5 years, Jazz Pharmaceuticals' Non Operating Income had its largest YoY gain of 2333.67% in 2016, and its largest YoY loss of 13648.11% in 2016.
  • Over the past 3 years, Jazz Pharmaceuticals' Non Operating Income (Quarter) stood at $2.1 million in 2015, then plummeted by 135.82% to -$749000.0 in 2016, then plummeted by 95.46% to -$1.5 million in 2017.
  • Its Non Operating Income stands at -$1.5 million for Q1 2017, versus -$749000.0 for Q3 2016 and -$819000.0 for Q1 2016.